
07/18/2025
At yesterday’s FDA panel on menopausal hormone therapy, experts reviewed outdated warning labels rooted in the 2002 WHI study and emphasized that newer formulations—like bioidentical estrogen, progesterone, vaginal estrogen, and testosterone—are safer and more beneficial than previously understood. The panel highlighted critical gaps in clinician education, reaffirmed estrogen’s bone-protective effects, and underscored that low-dose vaginal estrogen is highly effective and safe for Genitourinary Syndrome of Menopause. Dr. Rubin called for broader access to vaginal estrogen, and removal of the black box warning on vaginal estrogen products, while Dr. Casperson advocated for recognizing testosterone’s key role in women’s health, pointing to its physical, mental, and s*xual benefits. You can watch it on YouTube!